18 to the Storting (2004–2005). On course towards more correct use
(2006). A 26-week, randomized parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care.
(2008). Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes.
(2007). Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med.
(2004). Efﬁ cacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care.
Glargine versus NPH insulin: efﬁ cacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes – the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract.
Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration.
(2004). Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diab Res Clin Pract.
(1999). Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.
(2006). Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag.
(2006). Insulin glargine in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag.
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
(2008). Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev.
(2007). Long-term efﬁ cacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efﬁ cacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2). Endocr J.
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
(2006). On behalf of the Task Force on Insulin, Test Strips and Other Diabetes Supplies. Global access to and availability of insulin. Diabetes Voice.
(2005). Reduced Hypoglycemia Risk With Insulin Glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care.
(2005). Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care.
(2008). Safety and efﬁ cacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin.
(2004). The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res.
(2007). Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab.
(2008). Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodiﬁ ed human insulin in people with Type 1 diabetes. Diabetes Care.
(2006). Twice-daily compared with oncedaily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med.
(2008). Vascular Health and Risk Management 2009:5 128 Johansen et al 17. The Norwegian Labour and Welfare Organisation
(2005). Weight gain and insulin treatment. Diabetes Metab.